Immunovant, Inc.
IMVTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. The $8.27B market capitalization puts IMVT squarely in mid-cap range for its industry. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Market Cap
$8.27B
Beta
0.77
P/E (TTM)
—
P/E (Fwd)
-19.69
EPS (TTM)
$-2.86
EPS (Fwd)
$-2.05
ROE
-64.8%
ROA
-38.4%
Cash
$902.1M
Total Debt
$72,000
Free CF
-$234.3M
52W Change
124.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $902.1M in cash comfortably exceeding the $72K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$234.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -64.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Immunovant, Inc. and its sector.